|
Synonyms: APN01 | GSK-2586881 | GSK2586881 | rhsACE2
Compound class:
Peptide or derivative
Comment: Alunacedase alfa (APN01; Aperion Biologics) is a recombinant version of human ACE2 that is intended to act as a decoy (soluble trap) for the SARS-CoV-2 spike protein [1,4-5], than can neutralise the virus [4]. Recombinant ACE2 was originally proposed as a mechanism to combat acute respiratory distress syndrome (ARDS) caused by the SARS-CoV virus [2], which like SARS-CoV-2 uses ACE2 to infect host cells. Structurally APN01 is a glycosylated dimer of peptide chains that form the extracellular domain of the enzyme. It is produced in Chinese hamster ovary (CHO) cells, and it contains several intra-subunit disulphide bridges.
|
| No information available. |
Summary of Clinical Use  |
| Alunacedase alfa (APN01) is well-advanced as a drug candidate for the treatment of COVID-19. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04287686 | Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | N/A Interventional | The First Affiliated Hospital of Guangzhou Medical University | ||
| NCT00886353 | Safety and Tolerability Study of APN01 (Recombinant Human Angiotensin Converting Enzyme 2) | Phase 1 Interventional | Apeiron Biologics | ||
| NCT04335136 | Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 | Phase 2 Interventional | Apeiron Biologics | ||
| NCT01597635 | The Safety, Tolerability, PK and PD of GSK2586881 in Patients With Acute Lung Injury | Phase 2 Interventional | GlaxoSmithKline | 3 | |
